

## Clinical Policy: Tildrakizumab-asmn (Ilumya)

Reference Number: IL.PHAR.386

Effective Date: 1.1.20

Last Review Date: 4.17.25

[Revision Log](#)

Line of Business: Medicaid

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

Tildrakizumab-asmn (Ilumya™) is an interleukin-23 (IL-23) blocker.

### FDA Approved Indication(s)

Ilumya is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation® that Ilumya is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Plaque Psoriasis (must meet all):

1. Diagnosis of moderate-to-severe PsO as evidenced by involvement of one of the following (a or b):
  - a.  $\geq 3\%$  of total body surface area;
  - b. Hands, feet, scalp, face, or genital area;
2. Prescribed by or in consultation with a dermatologist or rheumatologist;
3. Age  $\geq 18$  years;
4. Member meets one of the following (a,b, or c):
  - a. Failure of a trial of  $\geq 3$  consecutive months of methotrexate (MTX) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
  - b. If intolerance or contraindication to MTX (*see Appendix D*), failure of a trial of  $\geq 3$  consecutive months of cyclosporine at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
  - c. Member has intolerance or contraindication to MTX and cyclosporine, and failure of phototherapy, unless contraindicated or clinically significant adverse effects are experienced;
5. Failure of at least TWO of the following, each used for  $\geq 3$  consecutive months, unless contraindicated or clinically significant adverse effects are experienced: Enbrel®, adalimumab-adbm, adalimumab-ryvk (Simlandi), Cimzia®; unless the member has had a history of failure of two TNF blockers;

*\*Prior authorization is required for Enbrel, adalimumab products, and Cimzia*

6. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (see Section III: Diagnoses/Indications for which coverage is NOT authorized);
7. Dose does not exceed 100 mg at weeks 0 and 4, followed by maintenance dose of 100 mg every 12 weeks.

**Approval duration: 6 months**

**B. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid

**II. Continued Therapy**

**A. Plaque Psoriasis** (must meet all):

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. Member does not have combination use with biological disease-modifying antirheumatic drugs or Janus kinase inhibitors (see Section III: Diagnoses/Indications for which coverage is NOT authorized);
4. If request is for a dose increase, new dose does not exceed 100 mg every 12 weeks.

**Approval duration: 12 months**

**B. Other diagnoses/indications** (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or

- b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

### III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents.
- B. Combination use with biological disease-modifying antirheumatic drugs (bDMARDs) or potent immunosuppressants, including but not limited to any tumor necrosis factor (TNF) antagonists [e.g., Cimzia<sup>®</sup>, Enbrel<sup>®</sup>, Humira<sup>®</sup> and its biosimilars, Remicade<sup>®</sup> and its biosimilars (Avsola<sup>™</sup>, Inflectra<sup>™</sup>, Renflexis<sup>™</sup>, Zymfentra<sup>®</sup>), Simponi<sup>®</sup>], interleukin agents [e.g., Actemra<sup>®</sup> (IL-6RA), Arcalyst<sup>®</sup> (IL-1 blocker), Bimzelx<sup>®</sup> (IL-17A and F antagonist), Cosentyx<sup>®</sup> (IL-17A inhibitor), Ilaris<sup>®</sup> (IL-1 blocker), Ilumya<sup>™</sup> (IL-23 inhibitor), Kevzara<sup>®</sup> (IL-6RA), Kineret<sup>®</sup> (IL-1RA), Omvoh<sup>™</sup> (IL-23 antagonist), Siliq<sup>™</sup> (IL-17RA), Skyrizi<sup>™</sup> (IL-23 inhibitor), Stelara<sup>®</sup> (IL-12/23 inhibitor), Taltz<sup>®</sup> (IL-17A inhibitor), Tofidence<sup>™</sup> (IL-6), Tremfya<sup>®</sup> (IL-23 inhibitor), Wezlana<sup>™</sup> (IL-12/23 inhibitor)], Janus kinase inhibitors (JAKi) [e.g., Cibinqo<sup>™</sup>, Olumiant<sup>™</sup>, Rinvoq<sup>™</sup>, Xeljanz<sup>®</sup>/Xeljanz<sup>®</sup> XR,], anti-CD20 monoclonal antibodies [Rituxan<sup>®</sup> and its biosimilars (Riabni<sup>™</sup>, Ruxience<sup>™</sup>, Truxima<sup>®</sup>), Rituxan Hycela<sup>®</sup>], selective co-stimulation modulators [Orencia<sup>®</sup>], integrin receptor antagonists [Entyvio<sup>®</sup>], tyrosine kinase 2 inhibitors [Sotyktu<sup>™</sup>], and sphingosine 1-phosphate receptor modulator [Velsipity<sup>™</sup>] because of the additive immunosuppression, increased risk of neutropenia, as well as increased risk of serious infections.

### IV. Appendices/General Information

#### Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration  
IL-23: interleukin-23

MTX: methotrexate  
PsO: plaque psoriasis

#### Appendix B: Therapeutic Alternatives

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
cyclosporine (Sandimmune <sup>®</sup> , Neoral <sup>®</sup> )	<b>PsO</b> 2.5 – 4 mg/kg/day PO divided BID	4 mg/kg/day
Methotrexate (Trexall <sup>®</sup> , Otrexup <sup>™</sup> ,	<b>PsO</b> 10 to 25 mg/week IM, SC or PO or 2.5 mg PO Q12 hr for 3 doses/week	30 mg/week

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Rasuvo <sup>®</sup> , RediTrex <sup>®</sup> , Rheumatrex <sup>®</sup> , Jylamvo <sup>®</sup> )		
Enbrel <sup>®</sup> (etanercept)	<b>PsO</b> <u>Initial dose:</u> 50 mg SC twice weekly for 3 months <u>Maintenance dose:</u> 50 mg SC once weekly	50 mg/week
Humira <sup>®</sup> , Amjevita <sup>®</sup> (adalimumab)	<b>PsO</b> <u>Initial dose:</u> 80 mg SC <u>Maintenance dose:</u> 40 mg SC every other week starting one week after initial dose	40 mg every other week
Cimzia <sup>®</sup> (certolizumab)	<b>PsO</b> 400 mg SC every other week. For some patients (with body weight ≤ 90 kg), a dose of 400 mg SC at 0, 2 and 4 weeks, followed by 200 mg SC every other week may be considered.	PsO: 400 mg every other week

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

#### Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): Serious hypersensitivity reaction to tildrakizumab or to any of the excipients
- Boxed warning(s): none reported

#### Appendix D: General Information

- Definition of failure of MTX or DMARDs
  - Child-bearing age is not considered a contraindication for use of MTX. Each drug has risks in pregnancy. An educated patient and family planning would allow use of MTX in patients who have no intention of immediate pregnancy.
  - Social use of alcohol is not considered a contraindication for use of MTX. MTX may only be contraindicated if patients choose to drink over 14 units of alcohol per week. However, excessive alcohol drinking can lead to worsening of the condition, so patients who are serious about clinical response to therapy should refrain from excessive alcohol consumption.
  - TNF blockers:
    - Etanercept (Enbrel<sup>®</sup>), adalimumab (Humira<sup>®</sup>), adalimumab-atto (Amjevita<sup>™</sup>), infliximab (Remicade<sup>®</sup>) and infliximab biosimilars (Avsola<sup>™</sup>, Renflexis<sup>™</sup>, Inflectra<sup>®</sup>), certolizumab pegol (Cimzia<sup>®</sup>), and golimumab (Simponi<sup>®</sup>, Simponi Aria<sup>®</sup>).

## V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
PsO	<u>Initial dose:</u> 100 mg SC at weeks 0 and 4 <u>Maintenance dose:</u> 100 mg SC every 12 weeks  Ilumya should only be administered by a healthcare professional.	100 mg every 12 weeks

## VI. Product Availability

Single-dose prefilled syringe: 100 mg/1 mL

## VII. References

1. Ilumya Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; December 2022. Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/761067s014lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761067s014lbl.pdf). February 7, 2024.
2. Menter A, Gottlieb A, Feldman SR, et al. American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2008;58:826-850.
3. Menter A, Korman NJ, Elmets CA, et al. American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. *J Am Acad Dermatol*. 2009;60:643-659.
4. Menter A, Korman NF, Elmets cA, et al. American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. *J Am Acad Dermatol*. 10.1016/j.jaad.2009.03.027.
5. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80:1029-72. doi:10.1016/j.aad.201811.057.
6. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2021. Available at: <https://www.clinicalpharmacology-ip.com>.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
New policy created, adapted CP.PHAR.386 Tildrakizumab-asmn (Ilumya) policy.	12.11.19	1.7.20
2Q2021 annual review: reviewed and updated references; <b>updated</b> diagnosis - Diagnosis of moderate-to-severe PsO as evidenced by involvement of one of the following (a or b): a. $\geq 3\%$ of total body surface area;	6.20.21	

Reviews, Revisions, and Approvals	Date	P&T Approval Date
b. Hands, feet, scalp, face, or genital area;		
2Q 2022 annual review: for PsO, allowed phototherapy as alternative to systemic conventional DMARD if contraindicated or clinically significant adverse effects are experienced; reiterated requirement against combination use with a bDMARD or JAKi from Section III to Sections I and II; references reviewed and updated.	7.26.22	
2Q 2023 annual review: added HCPCS code; for PsO, added TNFi criteria to allow bypass if member has had history of failure of two TNF blockers; template changes applied to other diagnoses/indications and continued therapy section; references reviewed and updated.	4.19.23	
2Q 2024 annual review: added Bimzelx, Zymfentra, Omvoh, Wezlana, Sotyktu, Tofidence, and Velsipity to section III.B; references reviewed and updated.	5.8.24	
2Q2025 annual review: updated preferred adalimumab products; references reviewed.	4.17.25	

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to

applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.